Detect Metabolic Disease Before Irreversible Beta-Cell Failure.
Beta Intercept™ T2D is a precision molecular diagnostic designed to identify active pancreatic beta-cell injury, declining beta-cell function, and metabolic dysfunction from a single blood sample. Powered by the Intercept IQ™ Molecular Intelligence Platform — combining cell-free DNA, epigenetic biomarkers, clinical laboratory markers, artificial intelligence, and longitudinal patient data.
- Beta-cell-derived cfDNA
- Methylation biomarkers
- Metabolic biomarker panel
- GLP-1 therapeutic monitoring
The biology fails silently — years before diagnosis.
More than 537 million adults live with diabetes globally and roughly 1 in 3 U.S. adults have prediabetes. Beta Intercept™ T2D detects active biology before traditional measures fully reflect disease progression.
Chronic overproduction drives ER stress and mitochondrial dysfunction.
One blood draw. A complete metabolic profile.
A quantitative molecular signal of active beta-cell injury combined with the standard metabolic panel — unified by Intercept IQ™ into a single interpretable score.
Quantitative beta-cell-derived cell-free DNA. Measures active beta-cell apoptosis in real time — the earliest molecular signal of metabolic disease biology.
Long-term glycemic exposure over ~90 days.
Endogenous insulin reserve — surrogate for residual beta-cell function.
Current circulating insulin — real-time beta-cell secretion.
Integrated molecular disease activity score across all biomarkers.
One platform. From blood draw to continuously learning intelligence.
Thirteen tightly instrumented stages — each contributing orthogonal evidence that resolves into a single, interpretable clinical result.
Single 6 mL draw at any CLIA collection site.
Proprietary low-input isolation preserves fragmentomic detail.
Cleanroom extraction protocol optimized for picogram inputs.
Bisulfite conversion resolves beta-cell-specific methylation.
Absolute quantitation of tissue-specific cfDNA copies.
HbA1c, C-Peptide, insulin, and metabolic panel integrated.
Reproducible, HIPAA-compliant, containerized pipelines.
Multi-task InterceptIQ models jointly infer disease state.
Federated learning across multi-institutional cohorts.
MD-signed report with molecular narrative.
HL7/FHIR delivery into the EHR.
Every result feeds a de-identified evidence corpus.
Models improve with every outcome and validation study.
Every biological system, one unified metabolic profile.
Beta Intercept™ T2D integrates orthogonal biological modalities. Each layer contributes independent evidence; Intercept IQ™ resolves them into a single disease signal.
The metabolic narrative — cell by cell.
Hover any stage to reveal the remaining beta-cell reserve, the BetaDx™ signal, circulating insulin production, and clinical disease stage.
Peak beta-cell output masks underlying dysfunction.
Thirteen data sources. One learning system.
Intercept IQ™ improves with every result — models retrain as new molecular data, patient outcomes, and clinical evidence enter the system.
Deployable across the adult metabolic care continuum.
A molecular readout for the therapies redefining metabolic care.
Serial testing may help evaluate changes in beta-cell injury and function over time alongside standard clinical assessment — across pharmacologic, procedural, and cellular interventions.
A molecular endpoint for the next generation of metabolic therapeutics.
Beta Intercept™ T2D integrates into pharmaceutical programs from discovery through post-market surveillance — with a focus on beta-cell biology.
Analytical performance — audited, reproducible, published.
Every assay parameter is validated to CLIA / CAP standards and re-verified with each reagent lot and platform release.
A collaborative research network across adult metabolic disease.
Active and planned collaborations with academic medical centers, obesity medicine groups, and pharmaceutical development partners. Selected collaborations shown.
A physician-facing report designed for clinical decisions.
Every result is interpreted, contextualized, and delivered via HL7 / FHIR into the existing electronic health record.
The patient demonstrates an elevated beta-cell cfDNA signal in the setting of a rising HbA1c and compensatory hyperinsulinemia. Findings are consistent with active beta-cell injury in early Type 2 Diabetes. Consider intensifying lifestyle intervention, evaluating incretin-based therapy, and re-testing in 90 days to assess molecular response.
One application within a platform built for many.
Beta Intercept™ T2D is the adult metabolic application of the Intercept IQ™ Platform. The same architecture extends across the full continuum of cardiometabolic disease.
- 01Metabolic DysfunctionCommercial
- 02PrediabetesCommercial
- 03Type 2 DiabetesCommercial
- 04Obesity MedicineCommercial
- 05GLP-1 MonitoringLate-stage
- 06Beta-Cell Replacement TherapyDevelopment
- 07Pancreatic TransplantationDevelopment
- 08Cardiometabolic DiseaseResearch
A category-defining opportunity in precision metabolic diagnostics.
Beta Intercept™ T2D addresses one of the largest and fastest-growing categories in healthcare — with a molecular platform positioned across screening, therapy selection, and monitoring.
Bring Beta Intercept™ T2D into your clinic, program, or trial.
Our scientific and commercial teams partner with clinicians, health systems, obesity medicine practices, and pharmaceutical development groups to deploy Beta Intercept™ T2D across the adult metabolic continuum.